The global pneumococcal vaccine market has been forecast to increase at a compound annual growth rate (CAGR) of 18% in terms of revenue through to 2015.
Key factors contributing to growth within the global pneumococcal vaccine market include the increase in the aging population, along with increase in market consolidation. However, the emergence of regional players could pose a challenge to the growth of this market.
Furthermore, the increased awareness about and accessibility to pneumococcal vaccines in developing nations, where incidence and prevalence of pneumococcal diseases are comparatively higher than the developed nations, is a key driver for the growth within the pneumococcal vaccine market.
In the US, the pneumococcal vaccine market has been forecast to increase at a CAGR of 4.0% over the next nine years, increasing from a value of $1.4 billion in 2010, to be worth $2 billion in 2019. This increase is set to be fuelled by the launch of Pfizer's Prevnar 13.
Over the next decade, Pfizer's Prevnar 13 is set to dominate the global pneumococcal vaccine market with sales that could reach $3.4 billion in infants and adults across the US and 5EU by 2019, leaving only marginal roles for its competitors. The commercial opportunity for MenACWY conjugate vaccines will largely remain restricted to the US, while a broad Men B vaccine could achieve blockbuster status.
Key players currently dominating the global pneumococcal vaccine market include GlaxoSmithKline plc. Merck and Co. Inc. and Pfizer Inc.
For more information on the global pneumococcal vaccine market, see the latest research: Global Pneumococcal Vaccine Market
Follow us on Twitter @CandMResearch
Companiesandmarkets.com issues news updates and report summaries covering all major industries and sectors. The service provides additional client monitoring and timely alerts to breaking industry and sector news leading the day's business headlines. News articles, written by our staff, contain additional analyst insight, providing value added insight for our readers. News updates and real-time alerts on newly-released market reports are also available from our Facebook page, Twitter feed @CandMResearch and RSS links. We also welcome inquiries from business journalists and the news media.